# BPIFB1

## Overview
BPIFB1 is a gene that encodes the protein BPI fold containing family B member 1, which is part of the BPI fold-containing family known for its role in host defense mechanisms. The protein is primarily expressed in the respiratory system, where it plays a crucial role in maintaining airway mucociliary clearance (MCC) by regulating the properties of mucus, thus contributing to effective respiratory health (Donoghue2023BPIFB1; Bingle2012BPIFB1). BPIFB1 is associated with goblet cells in the airway epithelium and interacts with mucin proteins, indicating its involvement in mucus formation and maintenance (De2017Association). Additionally, BPIFB1 has been implicated in various diseases, including respiratory conditions and nasopharyngeal carcinoma, highlighting its clinical significance (Donoghue2020BPIFB1; Wei2018BPIFB1).

## Function
BPIFB1, also known as LPLUNC1, is a protein that plays a significant role in the respiratory system, particularly in maintaining airway mucociliary clearance (MCC), which is crucial for host defense. It is involved in regulating the biophysical properties of mucus, ensuring its proper viscosity for effective clearance from the airways (Donoghue2023BPIFB1). BPIFB1 colocalizes with the mucin protein MUC5B in secretory granules and is present in mucus on the airway surface, indicating its role as a key component of the mucociliary apparatus (Donoghue2023BPIFB1).

In healthy human cells, BPIFB1 interacts with mucin proteins, suggesting a regulatory role in mucus formation and maintenance. This interaction is crucial for maintaining the proper rheological properties of mucus, which are essential for effective MCC (Donoghue2023BPIFB1). BPIFB1 is expressed in the airway epithelium and is associated with goblet cells, as evidenced by its strong double staining with MUC5AC, a mucin marker for goblet cells (De2017Association).

The protein is part of the BPI fold-containing family, which is involved in host defense mechanisms, particularly in the nasal, tracheal, and bronchial passages (Bingle2012BPIFB1). BPIFB1's role in innate immunity is suggested by its structural similarity to other innate immune molecules, although its specific functions in healthy human cells require further investigation (Saferali2015Polymorphisms).

## Clinical Significance
Mutations and alterations in the expression of the BPIFB1 gene have been implicated in several respiratory diseases. BPIFB1 is crucial for maintaining normal mucociliary clearance (MCC) in the airways, a process essential for respiratory health. Loss of BPIFB1 function leads to increased mucus viscosity and reduced MCC, which are significant factors in conditions such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF) (Donoghue2023BPIFB1; Donoghue2020BPIFB1).

In cystic fibrosis, BPIFB1 is upregulated, suggesting a potential role in the disease's pathophysiology. This upregulation may be part of an innate immune response or could be rendered non-functional due to chronic infection and inflammation in CF airways (Bingle2012BPIFB1). BPIFB1 has also been identified as a lung-specific autoantigen associated with interstitial lung disease (ILD), where autoantibodies to BPIFB1 are present in some patients, indicating a potential role in autoimmune lung conditions (Shum2013BPIFB1).

In nasopharyngeal carcinoma (NPC), BPIFB1 affects radiosensitivity by inhibiting vitronectin expression, which is involved in DNA damage repair pathways. This suggests BPIFB1 could be a therapeutic target to enhance radiosensitivity in NPC treatment (Wei2018BPIFB1).

## Interactions
BPIFB1, also known as BPI fold containing family B member 1, interacts with several proteins that play significant roles in cellular processes related to nasopharyngeal carcinoma (NPC). Notably, BPIFB1 interacts with vitronectin (VTN) and vimentin (VIM), which are involved in cell motility and the epithelial-mesenchymal transition (EMT) process. These interactions were identified through co-immunoprecipitation assays and mass spectrometry (Wei2017BPIFB1).

BPIFB1 binds to VTN, a component of the extracellular matrix, and inhibits the formation of the VTN/integrin αV (ITGAV) complex. This interaction suppresses the activation of the focal adhesion kinase (FAK) signaling pathway, which is crucial for cell migration and invasion. BPIFB1 overexpression reduces the formation of the VTN/ITGAV complex, thereby inhibiting NPC cell migration and invasion (Wei2017BPIFB1; Wei2018BPIFB1).

BPIFB1 also interacts with VIM, a marker of EMT, and inhibits its expression, thereby reducing NPC cell migration and invasion. The interaction between BPIFB1 and VIM is confirmed by colocalization studies, primarily at the cell membrane (Wei2017BPIFB1). These interactions highlight BPIFB1's role in modulating key pathways involved in NPC progression.


## References


[1. (Donoghue2023BPIFB1) Lauren J. Donoghue, Matthew R. Markovetz, Cameron B. Morrison, Gang Chen, Kathryn M. McFadden, Taraneh Sadritabrizi, Mark I. Gutay, Takafumi Kato, Troy D. Rogers, Jazmin Y. Snead, Alessandra Livraghi-Butrico, Brian Button, Camille Ehre, Barbara R. Grubb, David B. Hill, and Samir N. P. Kelada. Bpifb1 loss alters airway mucus properties and diminishes mucociliary clearance. American Journal of Physiology-Lung Cellular and Molecular Physiology, 325(6):L765–L775, December 2023. URL: http://dx.doi.org/10.1152/ajplung.00390.2022, doi:10.1152/ajplung.00390.2022. This article has 2 citations.](https://doi.org/10.1152/ajplung.00390.2022)

2. (Donoghue2020BPIFB1) BPIFB1 loss alters airway mucus properties and diminishes mucociliary clearance. This article has 2 citations.

[3. (Wei2018BPIFB1) Fang Wei, Le Tang, Yi He, Yingfen Wu, Lei Shi, Fang Xiong, Zhaojian Gong, Can Guo, Xiayu Li, Qianjin Liao, Wenling Zhang, Qianxi Ni, Jia Luo, Xiaoling Li, Yong Li, Cong Peng, Xiang Chen, Guiyuan Li, Wei Xiong, and Zhaoyang Zeng. Bpifb1 (lplunc1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting vtn expression. Cell Death &amp; Disease, March 2018. URL: http://dx.doi.org/10.1038/s41419-018-0409-0, doi:10.1038/s41419-018-0409-0. This article has 54 citations.](https://doi.org/10.1038/s41419-018-0409-0)

[4. (Shum2013BPIFB1) Anthony K. Shum, Mohammad Alimohammadi, Catherine L. Tan, Mickie H. Cheng, Todd C. Metzger, Christopher S. Law, Wint Lwin, Jaakko Perheentupa, Helene Bour-Jordan, Jean Claude Carel, Eystein S. Husebye, Filippo De Luca, Christer Janson, Ravishankar Sargur, Noémie Dubois, Merja Kajosaari, Paul J. Wolters, Harold A. Chapman, Olle Kämpe, and Mark S. Anderson. Bpifb1 is a lung-specific autoantigen associated with interstitial lung disease. Science Translational Medicine, October 2013. URL: http://dx.doi.org/10.1126/scitranslmed.3006998, doi:10.1126/scitranslmed.3006998. This article has 74 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/scitranslmed.3006998)

[5. (Bingle2012BPIFB1) Lynne Bingle, Kirsty Wilson, Maslinda Musa, Bianca Araujo, Doris Rassl, William A. Wallace, Elizabeth E. LeClair, Thais Mauad, Zhe Zhou, Marcus A. Mall, and Colin D. Bingle. Bpifb1 (lplunc1) is upregulated in cystic fibrosis lung disease. Histochemistry and Cell Biology, 138(5):749–758, July 2012. URL: http://dx.doi.org/10.1007/s00418-012-0990-8, doi:10.1007/s00418-012-0990-8. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00418-012-0990-8)

[6. (De2017Association) Elise G De Smet, Leen JM Seys, Fien M Verhamme, Bart M Vanaudenaerde, Guy G Brusselle, Colin D Bingle, and Ken R Bracke. Association of innate defense proteins bpifa1 and bpifb1 with disease severity in copd. International Journal of Chronic Obstructive Pulmonary Disease, Volume 13:11–27, December 2017. URL: http://dx.doi.org/10.2147/COPD.S144136, doi:10.2147/copd.s144136. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.2147/COPD.S144136)

[7. (Wei2017BPIFB1) Fang Wei, Yingfen Wu, Le Tang, Yi He, Lei Shi, Fang Xiong, Zhaojian Gong, Can Guo, Xiayu Li, Qianjin Liao, Wenling Zhang, Ming Zhou, Bo Xiang, Xiaoling Li, Yong Li, Guiyuan Li, Wei Xiong, and Zhaoyang Zeng. Bpifb1 (lplunc1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with vtn and vim. British Journal of Cancer, 118(2):233–247, November 2017. URL: http://dx.doi.org/10.1038/bjc.2017.385, doi:10.1038/bjc.2017.385. This article has 59 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/bjc.2017.385)

[8. (Saferali2015Polymorphisms) Aabida Saferali, Ma’en Obeidat, Jean-Christophe Bérubé, Maxime Lamontagne, Yohan Bossé, Michel Laviolette, Ke Hao, David C. Nickle, Wim Timens, Don D. Sin, Dirkje S. Postma, Lisa J. Strug, Paul J. Gallins, Peter D. Paré, Colin D. Bingle, and Andrew J. Sandford. Polymorphisms associated with expression of bpifa1/bpifb1 and lung disease severity in cystic fibrosis. American Journal of Respiratory Cell and Molecular Biology, 53(5):607–614, November 2015. URL: http://dx.doi.org/10.1165/rcmb.2014-0182OC, doi:10.1165/rcmb.2014-0182oc. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.1165/rcmb.2014-0182OC)